About this trial
Resistance exercise training (RET) in children and adolescents has become a popular area of research, with a growing body of evidence supporting its use. Position and consensus statements about RET for children indicate that it is safe and effective at increasing muscular strength, improving sport performance, and mitigating injury risk. Neural and muscular mechanisms can improve muscle strength following RET. Neural factors include improved recruitment and firing of an individual's motor units, and muscular factors primarily include an increase in the size of the muscle (hypertrophy).
In children, little is known about how these mechanisms relate to muscle strength. There is very little evidence of morphological changes following RET in children. Therefore, conventional wisdom is that children rely only on neural factors to improve strength following RET. Nevertheless, some studies have suggested RET-induced muscle hypertrophy in children and adolescents, indicating that with certain training protocols, children may achieve muscle growth.
Hypertrophy of muscle fibres occurs when the rate of muscle protein synthesis (MPS) is greater than the rate of protein breakdown, and is enhanced with the ingestion of dietary amino acids. Due to ethical concerns with obtaining muscle samples (i.e., from muscle biopsies) in pediatric populations, MPS rates have not been previously assessed following RET in children. Recent advancements in stable-isotope methodology (specifically, leucine) allow for the estimation of MPS in a non-invasive breath test.
The objective of the proposed research is to examine the effects of an acute bout of RET on leucine retention (a proxy for MPS) in children, adolescents, and adults using a non-invasive breath test.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
healthy
free of injury that would prevent resistance exercise
Disqualifiers
consumed any medications in the past year which may affect muscle function
had an injury in the past 6 months that would limit the movements required for the protocols
been told that has diabetes
been told that had a heart problem
Trial design
Single group
Treatments tested in this trial
exercise
Other interventionResistance exercise
Treatment groups
Trial outcomes
Primary outcomes
Leucine retention
retention is calculated as intake minus leucine in expired air (mg). This test involves blowing into a breath collection bag before, and every \~30 minutes after (for \~300 minutes) ingesting a powdered-amino acid supplement (modeled after egg protein - the WHO/FAO gold standard protein source) mixed with water. The supplement will contain 0.25 g/kg body mass of protein as crystalline amino acids, 0.75 g/kg body mass of carbohydrate (\~4kcal/kg of body mass), and will be enriched with 1 mg/kg of L-\[1-13C\]leucine (Cambridge Isotope Laboratories Inc., Tewksbury, MA, USA), which is a stable isotope that can be detected in the breath of the participants when not used for protein synthesis. The amount of the isotope that is expelled (oxidized) in the breath of the participant can be detected using continuous-flow isotope ratio mass spectrometry (ID-Microbreath; Compact Science Systems, Newcastle, UK), which allows for the estimation of leucine retention (intake - oxidation)
Secondary outcomes
body mass
mass in kg
body height
height in cm
arm circumference
arm circumference in cm
thigh circumference
circumference in cm
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Brock University
Lead sponsor
University of Toronto
Collaborator